Zai Lab

Zai Lab P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Zai Lab (9688.HK) as of Oct 16, 2026 is -14.46. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -79.72 — a change of -81.86% (higher).

P/CF

-14.46

YoY

-81.86%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Zai Lab is 2025 -14.46 . P/CF (Price-to-Cash-Flow Ratio) of Zai Lab was 2024 -79.72 . It decreases by -81.86% higher compared to the previous year.

The Zai Lab P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-22.39 USD
Jan 1, 2019
-11.43 USD
Jan 1, 2020
-10.11 USD
Jan 1, 2021
-3.98 USD
Jan 1, 2022
-5.94 USD
Jan 1, 2023
-11.02 USD
Jan 1, 2024
-79.72 USD
Jan 1, 2025
-14.46 USD
The Zai Lab P/CF history
YEARP/CFYoY
-14.46-81.86%
-79.72+623.41%
-11.02+85.51%
-5.94+49.39%
-3.98-60.66%
-10.11-11.59%
-11.43-48.94%
-22.39-66.82%
-67.47-87.33%
-532.64+179.63%
-190.48—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Zai Lab Stock analysis

What does Zai Lab do? Zai Lab Ltd is a biopharmaceutical company headquartered in Shanghai, China. The company has 1,194 employees and completed its initial public offering on September 28, 2020. Zai Lab focuses on discovering, licensing, developing, and commercializing proprietary therapeutics for significant unmet medical needs in the Chinese market. Its primary therapeutic areas include oncology, autoimmune diseases, and infectious diseases. The company maintains a diverse pipeline of drug candidates spanning from early discovery stages to late-stage clinical development. Among its pipeline assets are Niraparib (ZL-2306), ZL-2103, and ZL-1101, though specific details about these compounds are not provided. Zai Lab operates within the health care sector, specifically in the biotechnology industry. The company's website is www.zailaboratory.com, and it is listed on the Hong Kong Stock Exchange under the ticker symbol 9688.HK. The ISIN for the company is KYG9887T1168. Zai Lab's business model centers on addressing critical healthcare gaps in China through innovative drug development, with a particular emphasis on locally relevant medical conditions. The company does not disclose additional details about its product pipeline beyond the mentioned compounds, and its operations are based in Shanghai, China. Zai Lab is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zai Lab stock

P/CF (Price-to-Cash-Flow Ratio) of Zai Lab is -14.46 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Zai Lab changed from -79.72 to -14.46, representing a -81.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Zai Lab since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Zai Lab with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Zai Lab

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Zai Lab